Compare AESI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | PCRX |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | 790 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2023 | 2011 |
| Metric | AESI | PCRX |
|---|---|---|
| Price | $9.88 | $24.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $16.39 | ★ $33.83 |
| AVG Volume (30 Days) | ★ 3.1M | 718.5K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $1,117,218,000.00 | $716,791,000.00 |
| Revenue This Year | $4.55 | $6.24 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | ★ N/A | $50.90 |
| Revenue Growth | ★ 20.68 | 3.14 |
| 52 Week Low | $7.64 | $18.17 |
| 52 Week High | $26.86 | $27.64 |
| Indicator | AESI | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 55.94 |
| Support Level | $7.64 | $23.29 |
| Resistance Level | $9.40 | $24.81 |
| Average True Range (ATR) | 0.52 | 1.00 |
| MACD | 0.22 | 0.07 |
| Stochastic Oscillator | 85.46 | 64.85 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the most active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.